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OBJECTIVES: To examine the clinical and economic impact of diagnostic-driven 
(DD) versus empiric treatment strategies in neutropenic patients with suspected 
Aspergillus invasive fungal infections (IFIs) in Beijing, Chengdu, and Guangzhou, 
China. METHODS: A decision-analytic model was used to estimate total costs 
and survival associated with a DD and empiric treatment strategy for managing 
suspected IFIs in adult patients with neutropenia due to hematological malig-
nancy or autologous/allogeneic stem cell transplant. In the DD strategy, IFI was 
identified via serum galactomannan (GM) enzyme-linked immunosorbent assay 
(ELISA) so that early initiation of targeted treatment could be administered. IFI 
incidence (10.9%), portion of actual IFIs diagnosed via empiric treatment (30%), 
overall mortality (10.7%), and IFI-related mortality (28.6%) were obtained from 
the literature. Survival rates were generated based on the proportion of patients 
with identified and appropriately treated IFIs. Empiric and DD treatment pat-
terns and resource use were based on clinical opinion (3-5 clinicians from top 
hospitals per city). Medical costs (in 2014 Chinese Yuan [¥]) included antifungal 
drugs, treatment-related adverse events, and other medical resource costs. City-
specific costing sources were used wherever possible. RESULTS: Medical costs 
were lower for the DD versus the empiric strategy in Beijing (¥4,118 vs ¥5,245), 
Chengdu, (¥5,463 vs ¥6,389), and Guangzhou (¥9,762 vs ¥10,351). Fewer patients 
received antifungal treatment using the DD strategy (6.7% versus 11.4%), and sur-
vival rates were similar. One-way sensitivity analysis showed results were most 
sensitive to changes in GM test sensitivity followed by IFI incidence. Probabilistic 
sensitivity analysis showed that treating via a DD strategy was dominant 99% of 
the time. CONCLUSIONS: These results suggest that in China, a DD strategy to 
identify IFIs in immunocompromised patients with persistent fever in order to 
better target antifungal treatment compared to an empiric antifungal treatment 
strategy may be cost-saving, while maintaining a similar overall survival rate.
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OBJECTIVES: We aimed to assess cost-effectiveness of ceftaroline fosamil (CF) for 
treatment of hospitalised patients with pneumococcal community-acquired pneu-
monia (PCAP) in Russia from societal perspective. METHODS: Decision tree model 
based on results of two 3rd phase clinical trials (FOCUS1/FOCUS2) was created to 
assess clinico-economic implications of PCAP treatment with CF vs. ceftriaxone 
(CS) for society. Day 4 early clinical response (73% vs. 56%, p= 0,03) was taken for 
effectiveness outcome. Direct and indirect expenses associated with initial episode, 
possible recurrence of PCAP, direct and delayed attributive mortality were taken into 
consideration. Original drugs costs were extracted from wholesale prices database 
(www.pharmindex.ru). Cost of therapy was calculated to correspond treatment regi-
ments in selected trials: CF 600mg BID vs. CS 1g QD and common in Russia CS 2g 
QD. Alternative treatment in case of inefficacy was chosen per experts’ opinion. 
Indirect expenses evaluation was based on human capital approach (loss in GDP per 
capita) with 5% discount rate per year. All expenses were converted to US dollars at 
exchange rate on the date of calculation (June 2014). Uncertainty was explored in 
a series of one- and two-way deterministic and in probabilistic sensitivity analy-
sis. RESULTS: Respective total expenses of PCAP treatment with CF 600mg BID vs. 
CS 1g vs. CS 2g QD were as follows: $16548.6 vs. $16894.4 vs. $16972.3, making CF 
strategy the dominating one. Results were sensitive to change in rate of early clini-
cal response to comparators and duration of CF course. Given willingness-to-pay 
$12.8 per additional 1% of clinical response (per experts’ opinion) 95.1% and 97.3% 
of iterations in probabilistic sensitivity analysis recommended CF over CS 1g or 
2g QD for treatment of PCAP. CONCLUSIONS: CF 600mg BID is more cost effective 
then CS 1g or 2g QD in the treatment of hospitalised patients with PCAP in Russia 
from societal perspective.
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OBJECTIVES: CVC insertion is one of the most commonly performed medical pro-
cedures in the intensive care hospital setting. The clinical impact of SBT in the 
procedure has been demonstrated previously. However, little is known about the 
economic impact of such educational interventions. This study aimed to analyze 
the costs associated with outcomes attributable to the implementation of a SBT 
program for CVC insertion. METHODS: The SBT training interventions were imple-
mented for residents working in the MICU at OSF St. Francis Medical Center in 
Peoria, Illinois, from 09/01/2012 to 12/31/2013. Data from an historical control group 
(traditional training) was selected during a parallel time period from 09/01/2010 to 
12/31/2011. Collected information included total hospital cost, training cost, LOS, 
complications, and patient demographics. Costs were adjusted to 2014 dollars. 
Adjusted generalized linear models were used to estimate the margin effects for the 
cost and the effectiveness. RESULTS: 86 residents placed 353 CVC lines in patients 
three years (iPREX trial). The study objective was to estimate the cost-effectiveness 
of PrEP (Emtricitabine-Tenofovir combination pill) from the US payer perspective 
using both short-run and long-run outcomes. METHODS: We designed a decision 
analytical model using Excel® 2013 that mimicked the iPREX trial environment 
to compare costs and outcomes of PrEP plus usual care versus usual care alone 
(i.e. condom use). Outcomes included HIV cases averted over the trial period of 
3 years and life years gained (LYG) over a lifetime time horizon. Since the adher-
ence of PrEP was an important outcome measure in the trial, we factored in the 
PrEP adherence relationship of HIV acquisition into the model. Condom effective-
ness was defined as probability of remaining HIV negative, assuming consistent 
condom usage. All costs were adjusted to 2014. RESULTS: From our base-case 
analysis, the treatment arm (PrEP plus usual care) resulted in an incremental cost 
of $ 1,369,784 per HIV case averted over a 3-year time frame and an incremental 
cost of $ 34,973.50 per LYG over a lifetime time horizon. Our one-way sensitiv-
ity analysis suggested that condom effectiveness below 92% can make PrEP to 
be cost-saving per LYG. Our probabilistic sensitivity analysis suggested that the 
cost-effectiveness probability of PrEP is at least 50% if the payer is willing to pay 
a minimum of $45,000-$50,000 per LYG. CONCLUSIONS: The short-run value of 
PrEP from the US payer perspective may be greater than their willingness-to-
pay. Further research is warranted to understand subgroups where PrEP value 
differs as well as payers’ willingness-to-pay for HIV-specific and generic health 
outcomes.
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OBJECTIVES: An estimated 35 million people were living with HIV around the 
world in 2012. Although a toolbox of prevention methods including condoms, 
risk reduction counseling, voluntary circumcision, pre-exposure prophylaxis, and 
more are available, the development of an HIV vaccine is seen as the only hope 
for completely eradicating HIV. METHODS: A cost-effectiveness analysis of a par-
tially effective HIV vaccine in combination with pre-exposure prophylaxis (PrEP) 
for high risk people was performed from the perspective of a United States (US) 
healthcare payer using a patient’s lifetime horizon. Total direct costs, infections 
averted, and quality-adjusted life years (QALY) were the study outcomes. A deci-
sion tree modeled four preventive treatment strategies for high-risk men who have 
sex with men (MSM) in San Francisco: 1) vaccine and PrEP, 2) vaccine alone, 3) PrEP 
alone, and 4) no prevention strategy. RESULTS: A vaccine was found to be most 
cost-effective and dominant prevention strategy in this analysis. The incremental 
cost-effectiveness ratio (ICER) for a vaccine and PrEP combined was $45,704 per 
QALY, falling below a $100,000 per QALY willingness-to-pay threshold. An HIV vac-
cine alone was estimated to cost the payer $6,659 per infection averted and was a 
dominant strategy compared to no preventive intervention. PrEP alone cost more 
than $1.15 million at current pricing per infection averted, and combined with a 
vaccine, the cost per infection averted was reduced to $904,326. CONCLUSIONS: 
HIV incidence was the largest factor driving the cost per infection averted and 
cost per QALY for all prevention strategies, followed by the cost of PrEP for the 
two strategies that included it. US payers should actively advocate development, 
approval, coverage, and use of a vaccine to avert new HIV infections as a more 
cost-effective strategy than current preventive methods for people at high risk of 
HIV infection in the United States.
PIN54
rollINg out orAl PrE-ExPosurE ProPhylAxIs (PrEP) Is A cost-EffEctIVE 
hIV PrEVENtIoN strAtEgy AmoNg thE los ANgElEs couNty (lAc) mEN 
Who hAVE sEx WIth mEN (msm)
Drabo E.F.1, Hay J.W.1, Vardavas R.2, Wagner Z.3, Sood N.1
1University of Southern California, Los Angeles, CA, USA, 2Rand Corporation, Santa Monica, CA, 
USA, 3University of California, Berkeley, Berkeley, CA, USA
OBJECTIVES: We assess the tradeoffs between the costs and benefits of choosing 
alternate HIV prevention strategies, including the status-quo (current HIV testing 
with antiretroviral therapy [ART] initiation at CD4 ≤ 500), testing (expanded HIV 
testing with ART initiation at CD4 ≤ 500), test-and-treat (expanded HIV testing 
and early ART start), and PrEP (PrEP initiation by uninfected individuals) strate-
gies. METHODS: A mathematical epidemiological model is developed to simulate 
HIV incidence among 15-65 year old MSM in LAC. An economic model uses the 
epidemic model results to estimate the cost and effectiveness of 624 variants of 
the testing, test-and-treat and PrEP strategies from a societal perspective. For 
each strategy, we estimate the number of new HIV infections averted, the dis-
counted costs and quality-adjusted life years (QALYs), and the incremental cost-
effectiveness ratios. The sensitivity and robustness of the estimates are assessed 
via univariate and bootstrapping probabilistic sensitivity analyses. RESULTS: In 
the base case analysis, test-and-treat, PrEP, and testing are highly cost-effective 
relative to status-quo ($21 000, $26 000, and $27 500/QALY) and significantly reduce 
new infections. This is imputable to the preventive benefits of PrEP and early 
knowledge of infection status via testing, and the survival gains from early ART 
initiation. Thirteen strategies consisting of more aggressive test-and-treat and 
PrEP approaches trace the efficient frontier for decision making. More aggres-
sive strategies are more costly but yield better effectiveness profiles, albeit with 
diminishing returns. These results remain generally robust to uncertainty in the 
epidemic, cost, and effectiveness parameters. The relative effectiveness of PrEP is 
however sensitive to PrEP and ART adherence and initiation rates. CONCLUSIONS: 
PrEP and test-and-treat strategies are cost-effective alternatives to the status-quo 
for HIV prevention among LAC MSM. When affordable, aggressive combinations 
of these strategies should be implemented. The effectiveness of these strategies 
could be enhanced with greater adherence to ART and PrEP.
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effectiveness in the prevention of pneumonia due to influenza in the Colombian 
children and elderly population. METHODS: A probabilistic decision-tree model to 
simulate Influenza-Like Syndrome (ILS) burden of disease and influenza pneumo-
nia complications in Colombian population was programmed in excel. Transition 
probabilities and care costs for Colombia were obtained from a literature review 
and surveillance databases. Oseltamivir effectiveness was meta-analyzed from 
randomized trials and observational studies. Incremental cost-effectiveness ratio 
(ICER) for oseltamivir in the prevention of pneumonia complication in population 
under five years of age and older than 65 year old with ILS was estimated. Monte 
Carlo simulation with 10,000 iterations were used to estimate 95% confidence 
interval. Costs were expressed in 2013 USD. RESULTS: A total of 275,788 ILS cases 
in children and 86,675 in elderly population were estimated for 2014. Whit no 
oseltamivir would occur 75,789 and 62,817 pneumonias in children and elderly, 
respectively, and a total 22,719 deaths. Including the oseltamivir treatment at 
90% coverage would avert 33,462 pneumonias and 6639 pneumonia deaths. The 
oseltamivir cost were estimated on US$ 6,419,552, and it would be a cost-saving 
intervention in population younger than 5 years old and equal or older than 65 
years old with an ICER of US$ -953 (IC95% US$-934 to -759). CONCLUSIONS: The 
use of oseltamivir in children and elderly whit ILS appear to be a cost-saving 
strategy in Colombia, to prevent pneumonia and death complications, when it is 
administrated between 48 hours of symptoms onset.
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OBJECTIVES: To project the cost savings of introducing Fecal Microbiota Transplant 
(FMT) treatment for Clostridium difficile infection (CDI) as compared to current 
practice, by age, and three major subpopulations; hospitals, long-term care facilities 
(LTCF), and communities. METHODS: We modified our existing CDI decision ana-
lytic model to project the total cost savings of FMT as compared to current antibiotic 
treatment for CDI over five years (2015-2019), by integrating current annual trends 
in CDI, and population projections for Canada, by age, gender, and three major sub-
populations. To estimate current annual trends in CDI we conducted a systematic 
analysis of the latest provincial and federal CDI data in Canada. RESULTS: Over the 
next five years, CDI treatment with FMT is estimated to result in a potential cost 
savings of $300.4 M as compared to current practice. We projected 20,700 fewer cases 
of CDI in the FMT treatment arm, due to fewer recurrences for FMT. The recurrence 
rates for current antibiotic treatment were estimated at 25.3% and 35.9% for first 
and second recurrences, respectively. The recurrence rate for FMT was 10.4%. Over 
90% of the cost savings for FMT as compared to antibiotic treatment are for ages 60 
and over, with $127.3 M for ages 60 to 79 years, and $148.3 M for ages 80 and over. By 
subpopulation, over the next five years FMT would result in a potential cost savings 
of $216.5 M for hospital-acquired CDI (HA-CDI), and $68.7 M for community-acquired 
CDI (CA-CDI). CONCLUSIONS: Introducing FMT could result in a substantial cost 
savings over the next five years in Canada. As the Canadian population ages, and 
the numbers of CDI cases among the elderly might grow, FMT holds the promise of 
higher potential cost savings.
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OBJECTIVES: Chronic hepatitis C virus (HCV) incurs significant economic costs to 
the society. There is a paradigm shift in the treatment of hepatitis C with the intro-
duction of sofosbuvir. It is highly efficacious and safe but is an expensive treatment 
alternative to existing treatment options. The study goal is to provide an in-depth 
review of economic studies that have evaluated the cost-effectiveness of sofosbu-
vir in hepatitis C. METHODS: A comprehensive literature search was conducted 
using electronic databases such as PubMed, CINAHL, Scopus, and Cochrane Reviews. 
The search strategy included treatment-naïve as well as treatment-experienced 
patients of all genotypes. Full-text, published articles from Europe and United 
States (U.S.) were identified. Data on decision model, perspective, comparators, 
time horizon, costs, outcomes, price year, sensitivity analysis, and results were 
extracted from the reviewed studies. RESULTS: A total of 9 economic studies (5 
U.S. and 4 Europe) were identified from the literature. The comparators included 
no treatment, peginterferon+ribavirin, boceprevir, telaprevir, and simeprevir based 
regimens. Markov model utilized by all studies to simulate disease progression 
over a lifetime horizon. The cost/QALY for treatment-naïve, patients ranged from 
US$21,869-$31,152 for genotype 1 and US$78,146-$99,189 for genotype 2 and 3. The 
cost/QALY for treatment-experienced patients was US$2,277-$4290 for genotype 1 
and US$55,280-$128,324 for genotype 2 and 3. Overall, sofosbuvir was cost effec-
tive in younger patients and those with severe fibrosis. Sofosbuvir and simeprevir 
combination led to an average cost savings of US$91,590. CONCLUSIONS: Genotype 
1 HCV is the predominant genotype that is generally difficult to treat. Sofosbuvir 
is cost effective for both treatment-naïve and treatment-experienced genotype 1 
patients. For genotypes that are not predominant, decision on the use of sofosbuvir 
should be made based on the willingness-to-pay threshold values. Factors that were 
found to influence cost-effectiveness of sofosbuvir include disease severity, duration 
of treatment, and age of patients.
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with an average patient age of 63.4 (±15.8) years in the SBT group, and 81 residents 
placed 262 CVC catheter lines in patients with an average age of 62.8 (±15.2) years 
in the control group. Compared to the traditional training, the SBT was a dominant 
case with cost-saving (-$5,062, p= 0.002), and reductions of overall complications 
(3.9%, p= 0.017) and severe complications (3%, p= 0.043) per admission, resulted in 
the incremental cost-effectiveness ratios of -$1,298 (= -$5,062/3.9%) and -$1,687 (= 
-$5,062/3.0%) per 1% averted probability of overall and severe complications gained, 
respectively. The total benefit cost ratio was 10.2. Even in the first year, the SBT 
demonstrated a high return on investment (ROI) of 649% with a $4,863 net benefit 
per admission. The ROI could reach 934% and 986% in 5 years and 10 years, respec-
tively. CONCLUSIONS: Using SBT for CVC insertion is a cost-effective approach that 
can be widely implemented.
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OBJECTIVES: The aim of this analysis is to estimate the cost-effectiveness of anid-
ulafungin for the treatment of invasive candidiasis in Colombia. METHODS: We 
constructed a decision tree to determine the incremental cost-effectiveness ratio 
(ICER) of anidulafungin (200 mg on the first day, followed by 100 mg daily) compared 
to amphotericin B deoxycholate (0.7-1.0 mg daily); amphotericin B liposomal (5.0 
mg/ kg daily); caspofungin (70 mg on the first day followed by 50 mg daily) and 
fluconazole (800 mg on the first day followed by 400 mg daily) for the treatment the 
patients with invasive candidiasis. The perspective is that of the Colombian health 
system including only direct costs. All currency units are in USD $ (1 USD$ = COP 
1,971). We used a time horizon of life expectancy. A 5 % discount rate was used. The 
results were measured in quality-adjusted life year (QALY). The efficacy, safety and 
utility data were taken from the literature. Bayesian mixed treatment comparison 
method was applied for the comparison of treatments. The costs of procedures were 
obtained of ISS tariff manual of 2001 and for drugs were used current price regula-
tion and the SISMED database. Univariate and probabilistic sensitivity analyses 
were performed. RESULTS: The total expected costs per patient were: anidulafungin 
USD$ 4,685.61; amphotericin B deoxycholate USD$ 928.22; amphotericin B liposomal 
USD$ 25,569.12; caspofungin USD$ 3,368.48; fluconazole USD$ 628.39. The results for 
each alternative in terms of QALY were: anidulafungin 3.08; amphotericin B deoxy-
cholate 2.26; amphotericin B liposomal 1.90; caspofungin 2.14; fluconazole 2.46. 
The ICER per QALY of anidulafungin compared to fluconazole was USD$ 6,521.38. 
Amphotericin B deoxycholate, amphotericin B liposomal and caspofungin were 
dominated alternatives. CONCLUSIONS: Assuming as threshold for Colombia GDP 
per capita USD$ 7,609.42 anidulafungin is a cost-effective alternative for the treat-
ment of the patients with invasive candidiasis.
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OBJECTIVES: To assess the value of linezolid compared with vancomycin in the 
treatment of cSSSIs caused by MRSA from a payer perspective in the Kingdom of 
Saudi Arabia (KSA) using a two week decision analytic model. The model com-
prehensively covers direct medical costs within inpatient and outpatient settings 
related to both treatments. METHODS: Published literature and local expert opin-
ion provided clinical inputs and resource utilization data on MRSA efficacy, failure/
AE rates, length of stay (LOS), at-home parenteral administration, and outpatient 
resource use. Cost data were derived from local sources and expert feedback. 
The base case analysis assumed equal efficacy for treatment comparators within 
the 14 day length of treatment timeframe. Scenario-based sensitivity analyses 
were conducted by varying LOS data, using unit LOS costs from World Health 
Organization website, and excluding peripherally inserted central catheter (PICC) 
costs. RESULTS: The base case analysis resembled a cost-minimization analysis 
due to an equal efficacy assumption. Total drug acquisition costs were lower for 
vancomycin compared to linezolid (SAR1,885 vs. SAR7,641 respectively). However, 
the overall cost of treatment including drugs, clinical failures, complications, and 
outpatient parenteral administration were lower with linezolid (SAR14,246) than 
with vancomycin (SAR15,804) resulting in substantial cost-savings of SAR1,558 
vs. vancomycin. Linezolid provided savings due to lower outpatient medical costs 
(SAR1,548 vs. SAR7,831), specifically from outpatient parenteral administration. 
These findings were reinforced in all of the scenario sensitivity analyses, and 
linezolid was consistently the cost saving treatment alternative. CONCLUSIONS: 
Results from this analysis demonstrate the overall economic savings resulting 
from linezolid use compared with vancomycin for the treatment of MRSA cSSSI. 
Savings are seen primarily in the outpatient settings because linezolid has an oral 
formulation and does not require outpatient parenteral administration compared 
to other intravenous antibiotics.
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OBJECTIVES: Influenza disease may result in a severe disease causing hospitaliza-
tion and deaths in younger children and older adults. Early antiviral treatment 
may improve clinical outcomes. Our goal was to estimate the oseltamivir cost-
